Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb;392(2):209-217.
doi: 10.1007/s00210-018-1572-7. Epub 2018 Oct 29.

Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro

Izabela Zakrocka  1   2 , Katarzyna M Targowska-Duda  3 , Artur Wnorowski  3 , Tomasz Kocki  4 , Krzysztof Jóźwiak  3 , Waldemar A Turski  4
Affiliations

Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro

Izabela Zakrocka et al. Naunyn Schmiedebergs Arch Pharmacol. 2019 Feb.

Abstract

Glutamate (GLU) mainly through N-methyl-D-aspartate (NMDA) receptors plays pivotal role in kidney function regulation. Kynurenic acid (KYNA), a GLU receptors antagonist, is synthesized from kynurenine by kynurenine aminotransferases (KATs). Previously, it was shown that angiotensin II type 1 receptor blockers (ARBs) decrease KYNA production in rat brain in vitro. The aim of this study was to examine the influence of six ARBs: candesartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan on KYNA production on rat kidney in vitro. The effect of ARBs was determined in kidney homogenates and on isolated KAT II enzyme. Among tested ARBs, irbesartan was the most effective KYNA synthesis inhibitor with IC50 of 14.4 μM. Similar effects were observed after losartan (IC50 45.9 μM) and olmesartan administration (IC50 108.1 μM), whereas candesartan (IC50 475.3 μM), valsartan (IC50 513.9 μM), and telmisartan (IC50 669.5 μM) displayed lower activity in KYNA synthesis inhibition in rat kidney homogenates in vitro. On the other hand, valsartan (IC50 27.5 μM) was identified to be the strongest KAT II inhibitor in rat kidney in vitro. Candesartan, losartan, and telmisartan suppressed KAT II activity with IC50 equal to 83.2, 83.3, and 108.3 μM, respectively. Olmesartan and irbesartan were the weakest KAT II inhibitors with IC50 values of 237.4 and 809.9 μM, respectively. Moreover, molecular docking suggested that studied ARBs directly bind to an active site of KAT II. In conclusion, our results indicate that ARBs decrease KYNA synthesis in rat kidney through enzymatic inhibition of KAT II, which may have impact on kidney function.

Keywords: Angiotensin II type 1 receptor blockers; Kidney; Kynurenic acid; Nephroprotection; Rat; Renin-angiotensin system.

PubMed Disclaimer

References

    1. Altintas MM, Moriwaki K, Wei C, Möller CC, Flesche J, Li J, Yaddanapudi S, Faridi MH, Gödel M, Huber TB, Preston RA, Jiang JX, Kerjaschki D, Sever S, Reiser J (2014) Reduction of proteinuria through podocyte alkalinization. J Biol Chem 289:17454–17467. https://doi.org/10.1074/jbc.M114.568998 - DOI - PubMed - PMC
    1. Bądzyńska B, Zakrocka I, Sadowski J, Turski WA, Kompanowska-Jezierska E (2014) Effects of systemic administration of kynurenic acid and glycine on renal haemodynamics and excretion in normotensive and spontaneously hypertensive rats. Eur J Pharmacol 743:37–41. https://doi.org/10.1016/j.ejphar.2014.09.020 - DOI - PubMed
    1. Bozic M, Valdivielso JM (2015) The potential of targeting NMDA receptors outside the CNS. Expert Opin Ther Targets 19:399–413. https://doi.org/10.1517/14728222.2014.983900 - DOI - PubMed
    1. Buchli R, Alberati-Giani D, Malherbe P, Köhler C, Broger C, Cesura AM (1995) Cloning and functional expression of a soluble form of kynurenine/alpha-aminoadipate aminotransferase from rat kidney. J Biol Chem 270:29330–29335 - DOI - PubMed
    1. Costa CV, Ragazzi E, Caparrotta L et al (1999) Liver and kidney kynurenine aminotransferase activity in different strains of rats. Adv Exp Med Biol 467:629–635 - DOI - PubMed

Publication types

LinkOut - more resources